Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BTK C481T |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BTK C481T | Advanced Solid Tumor | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing BTK C481T were resistant to Imbruvica (ibrutinib) in culture (PMID: 27282255). | 27282255 | |
| BTK C481T | lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, lymphoma cells over expressing BTK C481T were resistant to Imbruvica (ibrutinib) in culture (PMID: 27282255). | 27282255 | |
| BTK C481T | Advanced Solid Tumor | predicted - sensitive | RN486 | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with RN486 resulted in reduced Btk activity in a cell line expressing BTK C481T in culture (PMID: 33526860). | 33526860 |